Stem definition | Drug id | CAS RN |
---|---|---|
anorexics | 2140 | 122-09-8 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.19 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
May 4, 1959 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cholecystitis chronic | 160.48 | 16.90 | 58 | 6077 | 10441 | 46669486 |
Injury | 88.72 | 16.90 | 61 | 6074 | 43966 | 46635961 |
Angle closure glaucoma | 74.24 | 16.90 | 22 | 6113 | 2117 | 46677810 |
Gallbladder disorder | 73.82 | 16.90 | 39 | 6096 | 17459 | 46662468 |
Anxiety | 67.47 | 16.90 | 100 | 6035 | 181857 | 46498070 |
Phospholipidosis | 59.79 | 16.90 | 10 | 6125 | 61 | 46679866 |
Emotional distress | 58.21 | 16.90 | 41 | 6094 | 30666 | 46649261 |
Carotid artery dissection | 56.60 | 16.90 | 11 | 6124 | 169 | 46679758 |
Arteriospasm coronary | 55.28 | 16.90 | 20 | 6115 | 3601 | 46676326 |
Drug abuse | 48.07 | 16.90 | 50 | 6085 | 63358 | 46616569 |
Cholelithiasis | 47.70 | 16.90 | 40 | 6095 | 38641 | 46641286 |
Subarachnoid haemorrhage | 41.83 | 16.90 | 23 | 6112 | 11130 | 46668797 |
Pregnancy | 39.67 | 16.90 | 31 | 6104 | 27106 | 46652821 |
Encephalomalacia | 30.36 | 16.90 | 8 | 6127 | 500 | 46679427 |
Deep vein thrombosis | 29.69 | 16.90 | 44 | 6091 | 79729 | 46600198 |
Spinal cord infarction | 29.39 | 16.90 | 7 | 6128 | 289 | 46679638 |
Psoriasis | 27.32 | 16.90 | 42 | 6093 | 78562 | 46601365 |
Stress cardiomyopathy | 26.32 | 16.90 | 15 | 6120 | 7769 | 46672158 |
Depression | 25.82 | 16.90 | 64 | 6071 | 170040 | 46509887 |
Paraesthesia | 25.50 | 16.90 | 51 | 6084 | 117386 | 46562541 |
Colitis ischaemic | 25.13 | 16.90 | 16 | 6119 | 10116 | 46669811 |
Renal vein thrombosis | 24.27 | 16.90 | 6 | 6129 | 290 | 46679637 |
Biliary dyskinesia | 23.49 | 16.90 | 10 | 6125 | 2763 | 46677164 |
Pain | 22.22 | 16.90 | 122 | 6013 | 476826 | 46203101 |
Suicidal ideation | 20.82 | 16.90 | 31 | 6104 | 56351 | 46623576 |
Pneumonia | 20.57 | 16.90 | 12 | 6123 | 376308 | 46303619 |
Anhedonia | 20.03 | 16.90 | 14 | 6121 | 10321 | 46669606 |
Device dislocation | 17.96 | 16.90 | 18 | 6117 | 21784 | 46658143 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 54.10 | 27.53 | 32 | 835 | 82040 | 29869571 |
Source | Code | Description |
---|---|---|
ATC | A08AA01 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
FDA PE | N0000175372 | Appetite Suppression |
FDA EPC | N0000175423 | Sympathomimetic Amine Anorectic |
FDA PE | N0000175651 | Increased Sympathetic Activity |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D019440 | Anti-Obesity Agents |
MeSH PA | D001067 | Appetite Depressants |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35337 | analeptic drug |
CHEBI has role | CHEBI:35470 | cns agent |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:37962 | adrenergic neuron agents |
CHEBI has role | CHEBI:48560 | dopamine agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Low blood pressure | indication | 45007003 | |
Obesity | indication | 414916001 | DOID:9970 |
Prevention of Hypotension During Spinal Anesthesia | indication | ||
Hypotension Secondary to Spinal Anesthesia | indication | ||
Heart valve disorder | contraindication | 368009 | DOID:4079 |
Alcoholism | contraindication | 7200002 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Feeling agitated | contraindication | 24199005 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Mild pre-eclampsia | contraindication | 41114007 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Substance abuse | contraindication | 66214007 | |
Psychotic disorder | contraindication | 69322001 | |
Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
Secondary glaucoma | contraindication | 95717004 | |
Angina pectoris | contraindication | 194828000 | |
Edema | contraindication | 267038008 | |
Syncope | contraindication | 271594007 | |
Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
Hypertensive urgency | contraindication | 443482000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.92 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.80 | WOMBAT-PK |
ID | Source |
---|---|
4019891 | VUID |
N0000147976 | NUI |
D05458 | KEGG_DRUG |
1197-21-3 | SECONDARY_CAS_RN |
4018166 | VANDF |
4018167 | VANDF |
4019891 | VANDF |
C0013326 | UMLSCUI |
CHEBI:8080 | CHEBI |
CHEMBL1574 | ChEMBL_ID |
CHEMBL1200912 | ChEMBL_ID |
D010645 | MESH_DESCRIPTOR_UI |
DB00191 | DRUGBANK_ID |
4771 | PUBCHEM_CID |
7269 | IUPHAR_LIGAND_ID |
1064 | INN_ID |
C045TQL4WP | UNII |
221138 | RXNORM |
1294 | MMSL |
41147 | MMSL |
5278 | MMSL |
5279 | MMSL |
d00806 | MMSL |
001864 | NDDF |
001865 | NDDF |
001866 | NDDF |
373343009 | SNOMEDCT_US |
426428004 | SNOMEDCT_US |
53480001 | SNOMEDCT_US |
6394006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0644 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |
phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0647 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5000 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-0597 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1308 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1310 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1366 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1398 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1438 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1445 | TABLET | 37.50 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1742 | CAPSULE | 15 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1743 | CAPSULE | 37.50 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-098 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-099 | CAPSULE | 15 mg | ORAL | ANDA | 9 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-116 | TABLET | 37.50 mg | ORAL | ANDA | 9 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-552 | TABLET | 30 mg | ORAL | ANDA | 31 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-592 | CAPSULE | 37.50 mg | ORAL | ANDA | 9 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-593 | CAPSULE | 30 mg | ORAL | ANDA | 19 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-602 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-620 | CAPSULE | 30 mg | ORAL | ANDA | 9 sections |
LOMAIRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-001 | TABLET | 8 mg | ORAL | ANDA | 17 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-025 | TABLET | 37.50 mg | ORAL | ANDA | 25 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-025 | TABLET | 37.50 mg | ORAL | ANDA | 25 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-026 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-027 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-028 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-029 | CAPSULE | 37.50 mg | ORAL | ANDA | 25 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-029 | CAPSULE | 37.50 mg | ORAL | ANDA | 25 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-067 | TABLET | 8 mg | ORAL | ANDA | 17 sections |
Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11534-157 | CAPSULE | 15 mg | ORAL | ANDA | 28 sections |